Migratory and antigen presentation functions of IFN-producing killer dendritic cells

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6598-6606

  Himoudi, Nourredine ^a   Yan, Mengyong ^a   Bouma, Gerben ^a   Morgenstern, Daniel ^a   Wallace, Rebecca ^a   Seddon, Ben ^b   Buddle, Jo ^a   Eddaoudi, Ayad ^a   Howe, Steven J ^a   Cooper, Nichola ^a   Anderson, John ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL ISOLATION; CELL KILLING; CELL MIGRATION; COCULTURE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DENDRITIC CELL; EMBRYO; FLUORESCENCE ACTIVATED CELL SORTING; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ANIMALS; ANTIGEN PRESENTATION; BETA 2-MICROGLOBULIN; CELL MOVEMENT; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; GENES, RAG-1; INTERFERONS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NIH 3T3 CELLS;

EID: 69249127441     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0501     Document Type: Article

References (37)

1. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5: 296-306.
2. Ferlazzo G, Tsang ML, Moretta L, et al. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343-51.
3. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-11.
4. Munz C, Steinman RM, Fujii S. Dendritic cell maturation by innate lymphocytes: coordinated stimulation of innate and adaptive immunity. J Exp Med 2005;202:203-7.
5. Taieb J, Chaput N, Menard C, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006;12:214-9.
6. Chan CW, Crafton E, Fan HN, et al. Interferonproducing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006;12:207-13.
7. Ullrich E, Bonmort M, Mignot G, et al. Therapyinduced tumor immunosurveillance involves IFN-producing killer dendritic cells. Cancer Res 2007;67:851-3.
8. Caminschi I, Ahmet F, Heger K, et al. Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med 2007; 204:2579-90.
9. + interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med 2007;204: 2569-78.
10. + cells identify them as a subset of NK cells. J Exp Med 2007;204: 2561-8.
11. Himoudi N, Nabarro S, Buddle J, et al. Bone marrowderived IFN-producing killer dendritic cells account for the tumoricidal activity of unpulsed dendritic cells. J Immunol 2008;181:6654-63.
12. Goldman JP, Blundell MP, Lopes L, et al. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor γ chain. Br J Haematol 1998;103:335-42.
13. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002;13:803-13.
14. Pletneva M, Fan H, Park J-J, et al. IFN-producing killer dendritic cells are antigen-presenting cells endowed with T-cell cross-priming capacity. Cancer Res 2009;69: 6607-14.
15. Mignot G, Ullrich E, Bonmort M, et al. The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol 2008; 180:6477-83.
16. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol 2006;176:1517-24.
17. + subset and are licensed by tumor cells. Cancer Res 2009;69:6590-7.
18. Robbins SH, Walzer T, Dembele D, et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 2008;9:R17.
19. + lymphoid progenitors. Blood 2007;109: 4825-931.
20. + T cells via OX40-40 ligand interactions. J Immunol 2004;173: 3716-24.
21. Hanna J, Bechtel P, Zhai Y, et al. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol 2004;173:6547-63.
22. Hanna J, Gonen-Gross T, Fitchett J, et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest 2004;114:1612-23.
23. Hanna J, Fitchett J, Rowe T, et al. Proteomic analysis of human natural killer cells: insights on new potential NK immune functions. Mol Immunol 2005;42:425-31.
24. Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101:3052-7.
25. Vanderheyde N, Aksoy E,Amraoui Z, et al. Tumoricidal activity of monocyte-derived dendritic cells: evidence for a caspase-8-dependent, Fas-associated death domainindependent mechanism. J Immunol 2001;167:3565-9.
26. Janjic BM, Lu G, Pimenov A, et al. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol 2002;168:1823-30.
27. Shi J, Ikeda K, Fujii N, et al. Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells. Cancer Sci 2005;96:127-33.
28. Hubert P, Giannini SL, Vanderplasschen A, et al. Dendritic cells induce the death of human papilloma-virus-transformed keratinocytes. FASEB J 2001;15: 2521-3.
29. Liu S, Yu Y, Zhang M, Wang W, Cao X. The involvement of TNF-a-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-β-stimulated human dendritic cells to tumor cells. J Immunol 2001; 166:5407-15.
30. Santini SM, Lapenta C, Logozzi M, et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000;191:1777-88.
31. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999;190:1155-64.
32. Vidalain PO, Azocar O, Lamouille B, et al. Measles virus induces functional TRAIL production by human dendritic cells. J Virol 2000;74:556-9.
33. Vidalain PO, Azocar O, Yagita H, Rabourdin-Combe C, Servet-Delprat C. Cytotoxic activity of human dendritic cells is differentially regulated by doublestranded RNA and CD40 ligand. J Immunol 2001;167: 3765-72.
34. Chaperot L, Blum A, Manches O, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 2006; 176:248-55.
35. Korthals M, Safaian N, Kronenwett R, et al. Monocyte derived dendritic cells generated by IFNa acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med 2007;5:46.
36. Lu G, Janjic BM, Janjic J, et al. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-α1β2, Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 2002;168:1831-9.
37. Ayres FM, Narita M, Takahashi M, et al. Human dendritic cells mediate anti-tumor activity against hematopoietic tumor cells without direct contact and Fas/FasL killing pathway. Oncol Rep 2004;11: 1017-23.